Evaluation of protective efficacy using a nonstructural protein NS1 in DNA vaccine- loaded microspheres against dengue 2 virus

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 3161-3169

  Huang, Shih Shiung ^a   Li, I Hsun ^b,c   Hong, Po Da ^a   Yeh, Ming Kung ^a,b  

^a NATIONAL TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^c TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Adjuvant; Dengue virus; Ns1 protein loaded plga peg microspheres; Vaccination

Indexed keywords

DENGUE VACCINE; DNA VACCINE; MEMBRANE PROTEIN; MICROSPHERE; NONSTRUCTURAL PROTEIN 1; POLYGLACTIN MICROSPHERE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DENGUE; DENGUE VIRUS 2; DNA IMMUNIZATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; DRUG SYNTHESIS; DRUG TARGETING; FEMALE; IMMUNOLOGICAL PARAMETERS; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PARTICLE SIZE; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN LOCALIZATION; PROTEIN SECRETION; PROVOCATION TEST; SINGLE DRUG DOSE; SOLVENT EXTRACTION; SURFACE PROPERTY; SURVIVAL RATE; VIRUS IMMUNITY; ZETA POTENTIAL;

ADJUVANT; DENGUE VIRUS; NS1 PROTEIN-LOADED PLGA/PEG MICROSPHERES; VACCINATION;

ANIMALS; DENGUE; DENGUE VIRUS; FEMALE; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED ICR; MICROSPHERES; PARTICLE SIZE; POLYETHYLENE GLYCOLS; POLYGLACTIN 910; VACCINES, DNA; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84882687280     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S49972     Document Type: Article

References (24)

1. Guy B, Almond JW. Towards a dengue vaccine: progress to date and remaining challenges. Comp Immunol Microbiol Infect Dis. 2008;31(2-3):239-252.
2. Hatch S, Mathew A, Rothman A. Dengue vaccine: opportunities and challenges. IDrugs. 2008;11(1):42-45.
3. Kitchener S, Nissen M, Nasveld P, et al. Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults. Vaccine. 2006;24(9):1238-1241.
4. Leng CH, Liu SJ, Tsai JP, et al. A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity. Microbes Infect. 2009;11(2):288-295.
5. Whitehead SS, Blaney JE, Durbin AP, Murphy BR. Prospects for a dengue virus vaccine. Nat Rev Microbiol. 2007;5(7):518-528.
6. Simasathien S, Watanaveeradej V. Dengue vaccine. J Med Assoc Thai. 2005;88 Suppl 3:S363-S377.
7. Blaney JE, Matro JM, Murphy BR, Whitehead SS. Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys. J Virol. 2005;79(9): 5516-5528.
8. Amexis G, Young NS. Multiple antigenic peptides as vaccine platform for the induction of humoral responses against dengue-2 virus. Viral Immunol. 2007;20(4):657-663.
9. Heegaard PM, Dedieu L, Johnson N, et al. Adjuvants and delivery systems in veterinary vaccinology: current state and future developments. Arch Virol. 2011;156(2):183-202.
10. Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces. 2010;75(1):1-18.
11. Scheerlinck JP, Greenwood DL. Particulate delivery systems for animal vaccines. Methods. 2006;40(1):118-124.
12. Wu SF, Liao CL, Lin YL, et al. Evaluation of protective efficacy and immune mechanisms of using a non-structural protein NS1 in DNA vaccine against dengue 2 virus in mice. Vaccine. 2003;21(25-26): 3919-3929.
13. Yeh MK, Chen JL, Chiang CH. Vibrio cholerae-loaded poly(DL lactide co-glycolide) microparticles. J Microencapsul. 2002;19(2):203-212.
14. Yeh M, Chiang C. Inactive Vibrio cholerae whole-cell vaccine-loaded biodegradable microparticles: in vitro release and oral vaccination. J Microencapsul. 2004;21(1):91-106.
15. Coombes AG, Yeh MK, Lavelle EC, Davis SS. The control of protein release from poly(DL-lactide co-glycolide) microparticles by variation of the external aqueous phase surfactant in the water-in oil-in water method. J Control Release. 1998;52(3):311-320.
16. O'Hagan DT. Microparticles and polymers for the mucosal delivery of vaccines. Adv Drug Deliv Rev. 1998;34(2-3):305-320.
17. Chadwick S, Kriegel C, Amiji M. Nanotechnology solutions for mucosal immunization. Adv Drug Deliv Rev. 2010;62(4-5):394-407.
18. Kamphorst AO, Guermonprez P, Dudziak D, Nussenzweig MC. Route of antigen uptake differentially impacts presentation by dendritic cells and activated monocytes. J Immunol. 2010;185(6):3426-3435.
19. Eldridge JH, Staas JK, Meulbroek JA, Tice TR, Gilley RM. Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. Infect Immun. 1991;59(9):2978-2986.
20. Ahsan F, Rivas IP, Khan MA, Torres Suarez AI. Targeting to macrophages: role of physicochemical properties of particulate carriers - liposomes and microspheres - on the phagocytosis by macrophages. J Control Release. 2002;79(1-3):29-40.
21. Chen JL, Yeh MK, Chiang CH. The mechanism of surface-indented protein-loaded PLGA microparticle formation: the effects of salt (NaCl) on the solidification process. J Microencapsul. 2004;21(8):877-888.
22. Yeh MK, Coombes AG, Chen JL, Chiang CH. Japanese encephalitis virus vaccine formulations using PLA lamellar and PLG microparticles. J Microencapsul. 2002;19(5):671-682.
23. Yeh MK, Davis SS, Coombes AG. Improving protein delivery from microparticles using blends of poly(DL lactide co-glycolide) and poly(ethylene oxide)-poly(propylene oxide) copolymers. Pharm Res. 1996;13(11):1693-1698.
24. Shen X, Xue JH, Yu CY, et al. Small envelope protein E of SARS: cloning, expression, purification, CD determination, and bioinformatics analysis. Acta Pharmacol Sin. 2003;24(6):505-511.